



Patent
Attorney's Docket No. 003300-737

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Kjell OLMARKER et al.)	Group Art Unit: 1647
)	
Application No.: 09/760,810)	Examiner: J. Seharaseyon
)	
Filed: January 17, 2001)	Confirmation No.: 4391
)	
For: USE OF CERTAIN)	
METALLOPROTEINASE INHIBITORS)	
FOR TREATING NERVE DISORDERS)	
MEDIATED BY NUCLEUS PULPOSUS)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c) and (e), a statement is enclosed.


I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: February 26, 2003

By: 
Mercedes K. Meyer
Registration No. 44,939

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Continuation of Disposition of Claims: Claims pending in the application are 1-3,5-7,9-11,13-15,17-19,21-23,25,26,28-30,32-34,36-38,40-42,44-46 and 48.